SELL and COVID-19: COVID-19 survivors had higher percentages of CD45RO−CD62L+, CD45RO+CD62L+ and CD45RO+CD62L− Th cells compared to the values observed in patients with poor outcomes in the acute stage of the disease (Figure 3B,C).